Cynosure Completes Very Successful IPO

Cynosure Completes Very Successful IPO

Firm News

Cynosure (Nasdaq: CYNO) closed a very successful IPO on December 14 to cap off the 2005 IPO season during which WilmerHale handled 11 IPOs — eight as issuer counsel and three as underwriter counsel — in the US and Europe.

Cynosure develops and markets aesthetic treatment systems that are used by physicians and other practitioners to perform non-invasive procedures to remove hair, treat vascular lesions, rejuvenate skin through the treatment of shallow vascular and pigmented lesions and temporarily reduce the appearance of cellulite. Cynosure’s IPO, which raised $86,250,000, was priced above the estimated price range at $15 per share and has traded up 25-50% since.

Serving as Cynosure’s counsel in the IPO were WilmerHale lawyers David Redlick, David Westenberg, Corey DuFresne, Jason Kropp and Dana Krueger.

WilmerHale’s other IPOs in 2005 were:

  • Gas Turbine Efficiency (LSE: GTE) — £5,400,000 — Counsel to Issuer
  • Icagen (Nasdaq: ICGN) — $40,000,000 — Counsel to Issuer
  • IRobot (Nasdaq: IRBT) — $118,680,000 — Counsel to Underwriters
  • NxStage Medical (Nasdaq: NXTM) — $63,250,000 — Counsel to Issuer
  • Speedel Holding (SWX: SPPN) — SWX Exchange — Counsel to Issuer
  • SPI Lasers (LSE: SPIL) — £12,000,000 — Counsel to Issuer
  • SSA Global Technologies (Nasdaq: SSAG) — $113,850,000 — Counsel to Underwriters
  • Unica (Nasdaq: UNCA) — $55,200,000 — Counsel to Issuer
  • VistaPrint (Nasdaq: VPRT) — $138,220,000 — Counsel to Issuer
  • Website Pros (Nasdaq: WSPI) — $68,000,000 — Counsel to Underwriters

Notice

We appreciate your interest in WilmerHale. While we are pleased to have you contact us, please keep in mind that merely contacting WilmerHale does not create an attorney-client relationship. Such a relationship will not arise until the Firm agrees in writing to represent you in connection with a particular matter. Importantly, unless and until this has occurred, you should not provide us with any confidential information, and we have no duty to keep confidential any information that we may receive from you. Thank you for your understanding.